Teva Gets PTAB To Review Cushing's Syndrome Drug Patent
The Patent Trial and Appeal Board will look at whether a patent covering Corcept Therapeutics Inc.'s flagship Cushing's syndrome medication Korlym is invalid, following a challenge from Teva Pharmaceuticals USA Inc....To view the full article, register now.
Already a subscriber? Click here to view full article